Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00192309 · ClinicalTrials.gov registry record · Phase 2

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

A Phase 2 study of Influenza, sponsored by MedImmune.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target
1
Study location

NCT00192309: Completed Phase 2 study of Influenza, sponsored by MedImmune.

NCT00192309 is a Phase 2 study of Influenza that has completed, run by MedImmune. The registered enrollment target is 31 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00192309, a Phase 2 study of Influenza, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A \& B, live, cold-adapted (liquid formulation CAIV-T; Wyeth, Marietta, PA).

Primary Outcome

The geometric mean titers for each strain between Day 0 and 28 were examined.

Conditions Studied

Influenza

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL TIV
  • BIOLOGICAL CAIV-T

Study Locations (1)

Connecticut

  • David M. Radin, MD - Stamford

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2001-09
Est. Completion 2001-12
Phase Phase 2
MedImmune

210 total trials

What the finished NCT00192309 record still lists

NCT00192309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00192309 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00192309 about?

NCT00192309 is a clinical study titled "Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.". The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trival...

What is the current status of trial NCT00192309?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2001-09. Estimated completion is 2001-12.

What conditions does trial NCT00192309 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT00192309?

The interventions under investigation include: Placebo (BIOLOGICAL), TIV (BIOLOGICAL), CAIV-T (BIOLOGICAL).

Who is sponsoring clinical trial NCT00192309?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00192309 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00192309's enrollment target sits among peer trials

31 138th of 156 higher than 17 of 156 other Influenza trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00192309, the US trial registry maintained by the National Library of Medicine. NCT00192309 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.